Every day for 10 years, a seemingly heart-healthy 53-year-old woman experienced rapid and irregular heartbeats. She had no personal or family history of hypertension or hyperthyroidism. She did not suffer from myocardial or coronary artery disease, or any abnormalities of the heart as best doctors and medical science could determine. Yet, she complained of heart palpitations and dizziness nearly to the point of fainting.
For the patient in this case study, her symptoms first appeared 10 years ago and they persisted through the years. The symptoms peaked in the morning and occurred more frequently as time went on. Doctors prescribed medication, but it proved to be ineffective.
As a next step, Mayo Clinic physician researchers explored and confirmed the presence of a genetic mutation that clearly established an inherited predisposition to atrial fibrillation.
Their study findings appear in the February issue of
Nature Clinical Practice Cardiovascular Medicine (
http://www.nature.com/clinicalpractice/cardio).
"Why certain patients develop atrial fibrillation while others do not, despite comparable environmental stress exposure, might ultimately depend on their genetic makeup," the authors write.
Atrial fibrillation is recognized more often in the elderly who have underlying structural heart disease. But in this study, Mayo Clinic researchers address the gene-based form of atrial fibrillation that affects younger people who do not otherwise harbor risk factors for the disease. The case was compared to 2,000 individuals who did not carry the mutation or suffer from atrial fibrillation.
The Mayo Clinic study is the first to identify an atrial fibrillation-associated genetic mutation of the ATP-sensitive potassium (KATP) channel. Researchers uncovered its role as a safeguard against atrial arrhythmia under stress conditions. The fail-safe mechanism present in most people to
provide electrical stability to the heart under stress was defective in this patient. The sequencing of
KATP channel genes, using genomic DNA extracted from the patient's peripheral white blood cells, revealed a genetic mutation.
The discovery of the genetic mutation's role in contributing to atrial fibrillation may ultimately improve physicians' ability to identify patients who have a hereditary predisposition to atrial fibrillation, which is often complicated by increased risk for stroke and heart failure.
"Our findings support the emerging understanding of atrial fibrillation in younger patients as an inherited disease of ion channels, the building blocks of electrical pathways," says Timothy Olson, M.D., a pediatric cardiologist and lead author of the study.
Because medications were ineffective in this case, the Mayo Clinic team treated the woman's atrial fibrillation by targeting high-energy radio waves to an area of the atrium -- an upper heart chamber -- most vulnerable to stress-induced electrical instability. This approach highlights the capacity to successfully treat patients who have genetic forms of atrial fibrillation.
"This case is a fine example of individualized medicine in practice, highlighting the benefit of translating molecular technology into an understanding of disease processes in the clinical setting," says Andre Terzic, M.D., Ph.D., a cardiologist and senior author of the study.
Source: Mayo Clinic
Related stories:
Mayo Clinic spearheads research to discover unsuspected gene for atrial fibrillation
Mayo Clinic researchers have found a gene mutation linked to one family's hereditary form of atrial fibrillation. Researchers hope this discovery will lead to better understanding of the disease and, eventually, better ways to predict, prevent and treat the heart rhythm problem.
Human genetic variation -- Science's 'Breakthrough of the Year'
In 2007, researchers were dazzled by the degree to which genomes differ from one human to another and began to understand the role of these variations in disease and personal traits.
Science and its publisher, AAAS, the nonprofit science society, recognize “Human Genetic Variation” as the Breakthrough of the Year, and identify nine other of the year’s most significant scientific accomplishments in the 21 December issue.
Genetic information makes it safer to prescribe common blood thinner
Doctors prescribing blood thinners have had to go through a lengthy trial-and-error process to arrive at the optimal dose for their patients. But now the process can be faster and safer, thanks to research conducted at Washington University School of Medicine in St. Louis.
Case Western Reserve University gets $4 million to make 'smart nanoparticles'
The School of Medicine received $4 million in funding from the State of Ohio's Third Frontier Initiative for Targeted Nanoparticles for Imaging and Therapeutics (TNIP), which will support the development and commercialization of sub-atomic particles for the early detection of breast cancers and new therapies for hemophilia. Case Western Reserve University will work in collaboration with local companies Cleveland NanoCrystals, Copernicus Therapeutics, Inc., iMedd, Inc., and Ricera Biosciences, Inc. Principal investigator for TNIP is Pamela B. Davis, M.D., Ph.D., professor of pediatrics and senior associate dean for research at the School of Medicine.
Lessening medication for atrial fibrillation does not reduce side effects
Reducing how often a patient receives amiodarone, a medication used for suppressing atrial fibrillation (irregular heart beat) but which causes side effects, did not decrease the overall amount of amiodarone-related and heart disease related side effects, but did increase the rate of atrial fibrillation recurrence and the risk of death from all causes and cardiovascular hospitalizations, according to a study in the October 15 issue of
JAMA.
Novel imaging approach may assist in predicting success of treatment for atrial fibrillation
University of Utah researchers have developed a magnetic resonance imaging (MRI)-based method for detecting and quantifying injury to the wall of the heart's left atrium in patients who have undergone a procedure to treat atrial fibrillation. The results of the study are published in the Oct. 7, 2008, issue of the
Journal of the American College of Cardiology.
Study provides insight on a common heart rhythm disorder
University of Iowa researchers and colleagues in France have identified a gene variant that causes a potentially fatal human heart rhythm disorder called sinus node disease. Also known as "sick sinus syndrome," the disease affects approximately one in 600 heart patients older than 65 and is responsible for 50 percent or more of the permanent pacemaker placements in the United States.
Blood-Thinning Drug Linked to Increased Bleeding in Brain
(PhysOrg.com) -- Patients who take the commonly used blood-thinning drug warfarin face larger amounts of bleeding in the brain and increased risk of mortality if they suffer a hemorrhagic stroke, new research from the University of Cincinnati (UC) shows.